Apogee is a pre-revenue clinical-stage biotech advancing a differentiated antibody platform, with Phase 2 APEX Part B data marking a potential inflection point. However, the company faces a critical cash runway of under two quarters (cash of $105.6M vs. quarterly burn of ~$96M), implying imminent dilution.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Apogee remains pre-revenue with R&D expenses climbing 31% year-over-year to $67.3M in Q2 2026, driving operating losses to -$96.0M and net losses to -$85.9M, reflecting negative operating leverage typical of late-stage development.
Apogee Therapeutics' lead antibody program, APG777, shows promise in treating atopic dermatitis and asthma, with broader potential in inflammatory and immunological disorders.
The investment narrative for Apogee Therapeutics hinges on the successful clinical development of its lead antibody program, APG333, and other biologics.
Apogee Therapeutics secured a public offering led by major financial institutions, indicating strong institutional confidence in the company's growth prospects.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$1.14-6.5% vs -$1.07 | — vs $10M |
Q2 2026 May 11, 2026 | -$1.06+0.9% vs -$1.07 | — vs — |
Q2 2026 Mar 2, 2026 | -$1.03+1.9% vs -$1.05 | — vs — |
Q4 2025 Nov 10, 2025 | -$1.11+0.9% vs -$1.12 | — vs — |
When you're drawing income from a portfolio, the check size matters less than whether it keeps coming every year. A blue-chip payout is funded by free cash flow left over after the business reinvests in itself.
Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma AbbVie reaffirms previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88 NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE).
Deutsche Bank AG acquired a new stake in Apogee Therapeutics Inc. (NASDAQ: APGE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 98,979 shares of the company's stock, valued at approximately $13,137,000. Deutsche Bank AG owned approximately 0.16% of
Benchmark APGE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Apogee Therapeutics, Inc. (APGE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $135.07 | — | — | — | — | — | — | |
| $955.47 | $98.43B | 20.94 | 0.99% | 28.51% | 15.07% | 0.36% | |
| $3.19 | $1.67B | -3.64 | 26.92% | -697.13% | -47.85% | — | |
| $28.26 | $3.53B | 129.28 | 91.34% | 5.88% | 14.18% | — | |
| $34.18 | $7.05B | -13.88 | — | -7173.52% | -63.01% | — | |
| $295.03 | $521.26B | 50.51 | 8.57% | 15.68% | — | 2.23% |
Apogee Therapeutics, Inc. (APGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Apogee Therapeutics, Inc. (APGE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Aug 10, 2026·SEC
Jun 22, 2026·SEC
Get notified when APGE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Apogee Therapeutics, Inc. (APGE) stock FAQ — growth, dividends, profitability & financials explained
No. Apogee Therapeutics, Inc. (APGE) reported a net loss of $255.8M in fiscal year 2025.
Apogee Therapeutics, Inc. (APGE) had negative free cash flow of $232.6M in fiscal year 2025.
